Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT00408252 | Efficacy of SU 011248 in Head And Neck Carcinoma | terminated | Phase 2 | 54 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 2 | Sep 19, 2019 |
| NCT02339558 | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 3 | Sep 13, 2019 | clinicaltrials |
| NCT02454179 | Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma(KEYNOTE147) | completed | Phase 2 | 78 | Acerta Pharma BVINDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01581970 | Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer | completed | Phase 2 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02789189 | Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical Trail | terminated | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 0 | Sep 6, 2019 | clinicaltrials |
| NCT03020329 | Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01309633 | Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 80 | National University Hospital, SingaporeOTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT03830385 | Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck | unknown | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT04015661 | Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC | unknown | Phase 2 | 92 | Fuzhou General HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT00894413 | A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract | completed | Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT01604772 | Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | May 1, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03932266 | Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma | unknown | Phase 2 | 73 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Apr 30, 2019 | clinicaltrials |
| NCT03325465 | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of ChicagoOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)(PICH) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Antoine LacassagneOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02216916 | Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy | unknown | Phase 2 | 49 | Yonsei UniversityOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT03843671 | Hyperbaric Radiation Sensitization of Head and Neck Cancers | unknown | Phase 2 | 400 | National Baromedical ServicesOTHER | 2 | Feb 18, 2019 | clinicaltrials |
| NCT03839602 | Delineation of Reducing Clinical Target Volume for Early-stage Nasopharyngeal Carcinoma Patients | completed | Phase 2 | 103 | Sun Yat-sen UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03121313 | Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+ | unknown | Phase 2 | 68 | Chang Gung Memorial HospitalOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03283293 | Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT | completed | Phase 2 | 112 | Sun Yat-sen UniversityOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00484601 | Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 11, 2019 | clinicaltrials |
| NCT01392235 | Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 58 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01621880 | Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma(BRAIN) | completed | Phase 2 | 112 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT00104871 | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01696955 | Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery | completed | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03246685 | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD | terminated | Phase 2 | 1 | HiberCell, Inc.INDUSTRY | 1 | Dec 14, 2018 | clinicaltrials |
| NCT00085293 | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | terminated | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT03744208 | SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 30 | Shi YuankaiUNKNOWN | 0 | Nov 16, 2018 | clinicaltrials |
| NCT01524692 | Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma(ACC) | completed | Phase 2 | 35 | University of VirginiaOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT03557112 | By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC | unknown | Phase 2 | 180 | Guiyang Medical UniversityOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT03701451 | Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Wei JiangOTHER | 1 | Oct 10, 2018 | clinicaltrials |
| NCT03096184 | A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers | unknown | Phase 2 | 38 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00055913 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02942693 | Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma | unknown | Phase 2 | 50 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT02775370 | A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck | unknown | Phase 2 | 68 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Sep 26, 2018 | clinicaltrials |
| NCT03639467 | Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01941992 | Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients(ROSAM) | completed | Phase 2 | 120 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT03666221 | Nimotuzumab for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 67 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 11, 2018 | clinicaltrials |
| NCT02507154 | Reactivating NK Cells in Treating Refractory Head and Neck Cancer(NKEXPHNC) | unknown | Phase 1 / Phase 2 | 31 | National University Hospital, SingaporeOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT01218048 | ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 40 | Robert FerrisOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT02048020 | Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer | completed | Phase 2 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT03612219 | Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma | unknown | Phase 2 | 240 | Wei JiangOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT03578575 | To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma | unknown | Phase 2 | 120 | China Medical University HospitalOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT01732640 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | terminated | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 26, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 1, 2019source: clinicaltrials